Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, analyzing, handling, or performing quality control of biospecimens used for basic or clinical cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Education

• Independent school districts
• Public and state institutions of higher education
• Private institutions of higher education

Government

• City or township governments
• State governments
• Federally recognized Native American tribal governments
• County governments
• Special district governments
• Public and Indian housing authorities

Business

• Small businesses
• For-profit organizations other than small businesses

Nonprofit

• Nonprofits non-higher education with 501(c)(3)
• Other Native American tribal organizations
• Nonprofits non-higher education without 501(c)(3)

Miscellaneous

• Other